Lung Impedance-Guided HFpEF Therapy
Non-Invasive Lung Impedance-Guided Preemptive Treatment in Heart Failure With Preserved Ejection Fraction
Presented by Michael Shochat — Hillel Yaffe Medical Center
Subspecialty: Heart Failure
Published in ACC.26 Late-Breaking
Key Result
Lung impedance-guided therapy reduced HF hospitalizations by 74% and HF mortality by 74% in HFpEF over 3+ years. Clinicians adjusted medications 2x more frequently with earlier intervention at the preclinical stage.
What did this trial find?
The IMPEDANCE-HFpEF trial evaluated non-invasive lung impedance-guided preemptive therapy using the Edema Guard Monitor in HFpEF patients, finding a 74% reduction in HF hospitalizations and 74% reduction in HF mortality over 3+ years. The source material contains coverage of the earlier IMPEDANCE-HF trial (HFrEF, presented at ACC 2016) with quotes from lead investigator Michael Shochat, but no direct quotes specifically about the newer IMPEDANCE-HFpEF trial were found. The available quotes from Shochat about the impedance-monitoring approach and earlier trial provide relevant context about the technology and therapeutic concept.
Why does this trial matter?
Quote supply is very limited for the specific IMPEDANCE-HFpEF trial. The source material contains no direct coverage of the HFpEF trial itself — only coverage of the earlier IMPEDANCE-HF trial (HFrEF) presented at ACC 2016 by the same investigator using the same device. No independent commentators, editorialists, or outside experts were found reacting specifically to the IMPEDANCE-HFpEF results. All available quotes are from the lead investigator and relate to the predecessor trial, making them contextually relevant but not directly about the HFpEF-specific findings.
Study Design
Randomized controlled trial with 3+ years follow-up
Clinical Implications
Lung impedance monitoring may enable early intervention before symptomatic congestion develops, with benefits even more pronounced in HFpEF than previously shown in HFrEF. This non-invasive approach could transform remote monitoring for HFpEF.
Abstract
The IMPEDANCE-HFpEF trial evaluated lung impedance-guided therapy using the CardioSet Edema Guard Monitor in patients with HFpEF. The device measures lung impedance to detect fluid accumulation before symptoms develop. Over 3+ years of follow-up, lung impedance-guided therapy was associated with a 74% reduction in heart failure hospitalizations and a 74% reduction in HF mortality. Clinicians using the device adjusted medications more than twice as frequently, with adjustments made significantly earlier in the development of lung congestion before patients experienced symptoms.